A divided federal appeals court ruled that the Trump administration can compel a telemedicine provider of gender-related treatments for minors to hand over records, reversing a lower court that had tried to shut the investigation down.
The 9th U.S. Circuit Court of Appeals sided 2-1 with the Justice Department on Friday, finding that a Seattle federal judge was wrong to quash a DOJ subpoena against QueerDoc, a Washington state-based telehealth company that prescribes puberty blockers and hormones to transgender youth. The ruling marks the first time an appellate court has upheld one of the administration's subpoenas targeting providers of gender-related medical procedures for children, the Associated Press reported.
Judge Carlos Bea, a George W. Bush appointee, wrote the majority opinion. Judge Daniel Bress, a Trump nominee, joined him. A third, unnamed judge dissented. The panel sent the case back to the lower court to weigh other arguments QueerDoc has raised, but on the central question of whether the president's policy goals tainted the subpoena, the majority was direct.
"Every President has law enforcement priorities, just as every President has signature policies (often, the former are components of the latter)."
That line from Bea's opinion cuts to the heart of what the lower court got wrong. The district judge had treated Trump's public opposition to gender-affirming care for minors as proof that the subpoena was issued in bad faith. The 9th Circuit majority rejected that reasoning. A president, the panel held, may direct the DOJ to exercise its statutory authority in a manner consistent with his broader policy goals, and that alone does not make an investigation illegitimate.
The QueerDoc case is one piece of a much larger DOJ effort. The department announced last year that it had issued more than 20 subpoenas to doctors and clinics providing gender-related treatments to minors as part of a healthcare fraud investigation. The DOJ has said it has reason to believe some providers may be misleading patients about the long-term side effects of puberty blockers and cross-sex hormones.
Federal judges have quashed many of those subpoenas. Some characterized the government's demands as efforts to intimidate providers into halting care. Until Friday, no appeals court had weighed in, and the lower-court trend had given the ACLU and its allies reason to believe the legal landscape was tilting their way.
That changed with the 9th Circuit's ruling. The decision is notable not only because it reversed a specific district court order but because it established, for the first time at the appellate level, that the administration's enforcement posture is legally defensible. In a legal environment where federal judges have not hesitated to rule against the administration on other fronts, a win in the historically left-leaning 9th Circuit carries particular weight.
Beyond the procedural holding, the majority opinion ventured into territory that gender-care advocates have long tried to foreclose. The panel described the efficacy and long-term risks of gender-affirming treatments as "uncertain" and called the broader discussion around these procedures "an unsettled scientific debate."
The majority also said the Trump administration could justify its opposition to such treatments on ethical or philosophical grounds, not just medical ones. That framing undercuts the argument, advanced by progressive medical organizations, that restricting access to puberty blockers and hormones for minors is inherently anti-science. The court treated the question as genuinely open, not settled.
Most major medical groups maintain that access to gender-affirming care is important for individuals diagnosed with gender dysphoria and view gender as existing along a spectrum. But the 9th Circuit's language suggests at least some federal judges are unwilling to defer to that institutional consensus as though it were beyond challenge, particularly when the government is investigating whether patients are being told the full truth about risks.
The administration has grounded its investigation in a drug safety law, though the specific statute has not been publicly identified in court filings covered so far. Trump's executive order on the subject directs the DOJ to "prioritize investigations" into any entity "that may be misleading the public about long-term side effects of chemical and surgical mutilation." A separate executive order defines sex as only male or female and as unchangeable.
The subpoena at issue is not a narrow request. It seeks QueerDoc's personnel files, billing documents, communications with drug manufacturers, and records of patients who were prescribed puberty blockers or hormone therapy, among other information. QueerDoc, represented by the ACLU, has argued the demand is overbroad and burdensome.
The breadth of the request explains why the case has drawn national attention. If the subpoena is ultimately enforced, the DOJ would gain access to a detailed picture of how one telemedicine provider screens, treats, and bills for gender-related care, and what, exactly, patients are told before treatment begins. For an administration that believes some providers are cutting corners or concealing risks, those records are the whole ballgame.
Assistant Attorney General Brett Shumate, who leads the DOJ's Civil Division, framed the ruling in blunt terms. "The trans medical industry is not above the law," Shumate said.
That statement reflects the administration's broader posture: this is a law enforcement matter, not a culture-war exercise. Whether providers are complying with drug safety requirements and giving patients honest information about risks are questions any administration would be entitled to ask. The fact that the treatments in question are politically charged does not place them beyond the reach of a federal subpoena.
The ACLU's attorney, Adrien Leavitt, signaled that the organization is not backing down. Leavitt noted that the 9th Circuit was the first appeals court to rule on any of the DOJ's gender-care subpoenas and said the fight would continue on remand.
"We're ready to continue defending one of the most fundamental principles of healthcare: every patient's right to confidential medical care."
Leavitt's framing, casting the dispute as a patient-privacy issue, is the ACLU's strongest rhetorical card. But it sidesteps the government's core argument: that confidentiality does not shield providers from a fraud investigation. A patient's right to privacy is real, but it has never been treated as absolute when a federal agency has articulable grounds to suspect violations of law.
The case now returns to the district court, where QueerDoc can press additional arguments the 9th Circuit did not resolve. The specific nature of those arguments has not been detailed in available reporting. But the appellate ruling has already narrowed the playing field: the lower court can no longer rely on the theory that Trump's policy goals, standing alone, make the subpoena illegitimate.
The ruling lands at a moment when the administration's record in federal court has been mixed. Trump has won significant victories on some executive actions while facing setbacks on others. And the broader conservative legal movement has had its own internal tensions, as recent Supreme Court rulings have shown.
But on the specific question of whether the federal government can investigate what gender-care providers are telling children and their parents about powerful drugs, the 9th Circuit has now answered clearly: yes, it can.
The ruling's significance extends beyond QueerDoc. With more than 20 subpoenas outstanding and lower courts divided, the 9th Circuit's decision gives the DOJ a template for defending its investigation against future challenges. Other appeals courts will eventually weigh in. For now, the administration has the precedent it needed.
Meanwhile, federal courts continue to shape the boundaries of executive authority across a range of policy areas. Each ruling adds a brick to the legal wall that will define what this administration can and cannot do. On gender medicine for minors, the 9th Circuit just laid one squarely on the president's side.
When the government asks whether children are being told the truth about what's being done to their bodies, the answer should never be "you're not allowed to ask." Friday's ruling got that much right.
